Purdue Creditors Granted Right to Sue Sacklers for $11.5 Billion
Creditors can now pursue $11.5B in claims against Purdue Pharma's Sackler family, with mediation ongoing. Supreme Court nixed prior $6B settlement deal.
In a major development in the Purdue Pharma bankruptcy proceedings, U.S. Bankruptcy Judge Sean H. Lane granted Purdue Pharma’s creditors the right to pursue $11.5 billion in claims against certain members of the Sackler family, the owners of Purdue. The ruling enables the creditors, through their official committee, to seek recovery of funds that were allegedly moved improperly out of Purdue Pharma and into offshore trusts for the Sacklers' benefit. This decision comes amid ongoing mediation efforts, which could potentially avert litigation if a new settlement is reached.
The Prior Settlement and Supreme Court Intervention
Previously, the Sacklers had agreed to contribute $6 billion to a trust benefiting opioid victims and other creditors as part of Purdue’s bankruptcy plan. In exchange, the Sacklers were granted broad liability releases, shielding them from future opioid-related lawsuits. However, in a pivotal June ruling, the U.S. Supreme Court invalidated these third-party releases, deeming them nonconsensual. The invalidation of this settlement opened the door for renewed litigation, which the creditors are now authorized to pursue if mediation fails.
Concerns Over Litigation
While the committee of unsecured creditors supports the court’s decision, there are concerns about the drawn-out nature of litigation. Chris Shore, an attorney representing more than 60,000 individual opioid victims, emphasized the burden that prolonged litigation could impose on victims and the courts. Describing potential lawsuits as a “litigation conflagration,” Shore expressed hope that mediation could still yield a resolution, thus avoiding the costly and time-consuming path of pursuing claims through the courts.
“Litigation is never going to be the best solution,” Shore stated, underscoring the challenges posed by intricate legal issues and the complex structure of the Sacklers’ offshore holdings.
The Legal Teams Involved
Purdue Pharma’s unsecured creditors are represented by a team from Akin Gump Strauss Hauer & Feld LLP, including Mitchell P. Hurley and Arik Preis. Purdue itself is represented by Davis Polk & Wardwell LLP, while the individual victims are represented by attorneys from White & Case LLP and ASK LLP. A separate group of Canadian municipal and First Nations creditors, who have also voiced concerns about the committee’s role in these claims, is represented by Lite DePalma Greenberg & Afanador LLC.
What’s Next?
With the court’s ruling, the creditors’ committee is now equipped to file lawsuits against the Sacklers if mediation does not lead to an agreement by December. A complex network of deadlines complicates the path forward, including a litigation hold set to expire on November 1 and a December 1 deadline for tolling agreements. As the case progresses, the outcome could shape future bankruptcy cases involving similar third-party release provisions and set a precedent in the accountability of corporate owners for actions taken prior to bankruptcy.
About the author
Zach Barreto
Zach Barreto is a distinguished professional in the legal industry, currently serving as the Senior Vice President of Research at the Expert Institute. With a deep understanding of a broad range of legal practice areas, Zach's expertise encompasses personal injury, medical malpractice, mass torts, defective products, and many other sectors. His skills are particularly evident in handling complex litigation matters, including high-profile cases like the Opioids litigation, NFL Concussion Litigation, California Wildfires, 3M earplugs, Elmiron, Transvaginal Mesh, NFL Concussion Litigation, Roundup, Camp Lejeune, Hernia Mesh, IVC filters, Paraquat, Paragard, Talcum Powder, Zantac, and many others.
Under his leadership, the Expert Institute’s research team has expanded impressively from a single member to a robust team of 100 professionals over the last decade. This growth reflects his ability to navigate the intricate and demanding landscape of legal research and expert recruitment effectively. Zach has been instrumental in working on nationally significant litigation matters, including cases involving pharmaceuticals, medical devices, toxic chemical exposure, and wrongful death, among others.
At the Expert Institute, Zach is responsible for managing all aspects of the research department and developing strategic institutional relationships. He plays a key role in equipping attorneys for success through expert consulting, case management, strategic research, and expert due diligence provided by the Institute’s cloud-based legal services platform, Expert iQ.
Educationally, Zach holds a Bachelor's degree in Political Science and European History from Vanderbilt University.
Subscribe to our newsletter
Join our newsletter to stay up to date on legal news, insights and product updates from Expert Institute.
Sign up nowA Sample Voir Dire: How To Qualify An Expert Witness
Download free white paperChallenging Opposing Experts: Advanced Research Techniques
Download free white paperCross Examining Expert Witnesses: The Ultimate Guide
Download free white paper
Subscribe to our newsletter
Join our newsletter to stay up to date on legal news, insights and product updates from Expert Institute.